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The self-assembly of α-synuclein is closely associated with Parkinson’s
disease and related syndromes. We show that squalamine, a natural
product with known anticancer and antiviral activity, dramatically
affects α-synuclein aggregation in vitro and in vivo. We elucidate
the mechanism of action of squalamine by investigating its interaction
with lipid vesicles, which are known to stimulate nucleation, and find
that this compound displaces α-synuclein from the surfaces of such
vesicles, thereby blocking the first steps in its aggregation process. We
also show that squalamine almost completely suppresses the toxicity
of α-synuclein oligomers in human neuroblastoma cells by inhibiting
their interactions with lipid membranes. We further examine the ef-
fects of squalamine in a Caenorhabditis elegans strain overexpressing
α-synuclein, observing a dramatic reduction of α-synuclein aggrega-
tion and an almost complete elimination of muscle paralysis. These
findings suggest that squalamine could be a means of therapeutic
intervention in Parkinson’s disease and related conditions.
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The aggregation of α-synuclein (Fig. 1A), an intrinsically dis-ordered protein expressed at high levels in the brain, is
closely associated with the pathogenesis of a variety of neuro-
degenerative disorders, collectively known as α-synucleino-
pathies, including Parkinson’s disease (PD), dementia with Lewy
bodies (DLB), and multiple-system atrophy (MSA) (1–7). It has
been exceptionally challenging, however, to develop effective
strategies to suppress the formation of α-synuclein aggregates
and their associated toxicity (8, 9), because the mechanism of
aggregation of this protein is extremely complex and highly de-
pendent on environmental factors, such as pH, temperature, and
contact with surfaces (10). In particular, it is well established that
phospholipid binding can accelerate fibril formation (11); moreover,
it has recently been shown that such acceleration occurs through the
enhancement of the initial primary nucleation step in the aggrega-
tion process (12). In the light of this information, we decided to
investigate whether compounds capable of altering the binding of
α-synuclein to lipid membranes could be effective in inhibiting its
aggregation. This study was stimulated by our recent finding that a
small molecule, bexarotene, can suppress significantly the primary
nucleation reaction that initiates the production of the Aβ42 ag-
gregates linked with Alzheimer’s disease (AD) and reduces the as-
sociated toxicity in aCaenorhabditis elegansmodel of this disease (13).
In the present work, we have focused on one particular com-
pound, squalamine (Fig. 1B), an antimicrobial aminosterol origi-
nally discovered in 1993 in the dogfish shark, Squalus acanthias
(14). This small molecule, now prepared synthetically (see
SI Materials and Methods for details), has been found to
have pharmacological activity in endothelial cells by inhibiting
growth factor-dependent pathways and thus has emerged as a drug
candidate for the treatment of cancer and macular degeneration (15,
16). In the present context, our choice of studying squalamine was
prompted by the observation that this molecule is able to enter
eukaryotic cells and displace proteins that are bound to the cyto-
plasmic face of plasma membranes (17–19), suggesting that it may
influence the initiation of the aggregation of α-synuclein (12). Indeed
squalamine has been referred to as a “cationic lipid” (18) as it carries a
net positive charge and shows a high affinity for anionic phospholipids
(20) of the type that nucleates the aggregation of α-synuclein, thereby
reducing the negative charge of the membrane surface to which it is
bound (18, 21) without significantly disrupting the integrity of lipid
surfaces (18). In analogy, it has recently been shown that a homolo-
gous protein, β-synuclein, can inhibit α-synuclein lipid-induced aggre-
gation via a competitive binding at the surface of lipid vesicles (22).
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Because of these properties, we investigated the possibility
that squalamine could be effective in interfering with the mem-
brane-induced aggregation of α-synuclein. We first investigated
the possible mechanism of action of squalamine in this regard by
detailed biophysical studies in vitro and extended those results by
testing the effects of squalamine on the toxicity of α-synuclein
oligomers, using human neuroblastoma cells in culture (23, 24),
and then carried out experiments in vivo, using a well-established
C. elegans animal model of PD (25).
Results
Squalamine Displaces α-Synuclein from Lipid Membranes. To study
whether or not squalamine can affect the binding of α-synuclein
to lipid bilayers, we first used small unilamellar vesicles (SUVs)
with diameters of about 30 nm composed of 30% 1,2-dioleoyl-sn-
glycero-3-phospho-L-serine (DOPS), 50% 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine (DOPE), and 20% 1,2-dioleoyl-sn-glycero-3-
phosphocholine (DOPC), which represent the most abundant lipids
found in the membranes of synaptic vesicles (26). Titrating squal-
amine into a solution of α-synuclein bound to DOPS:DOPE:DOPC
(30:50:20) vesicles was observed to reduce the α-helical content of
α-synuclein in an approximately linear manner with squalamine
concentration, as measured by circular dichroism (CD) (Fig. 1 C
and D). This observation suggests that squalamine is able to
displace α-synuclein from the surface of lipid bilayers.
The physiological concentration of α-synuclein in neuronal syn-
apses is estimated to be about 50 μM (27, 28), a concentration of
protein that can be studied by NMR spectroscopy (27, 29–32). We
therefore used this technique to probe potential interactions be-
tween α-synuclein and squalamine in the absence of lipids and to
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Fig. 1. Squalamine displaces α-synuclein from DOPS:DOPE:DOPC (30:50:20) vesicles. (A) Amino acid sequence of α-synuclein and its three distinct regions (44),
the N-terminal region (blue), the central region (gray), and the C-terminal fragment (green). (B) Structure of squalamine (21). (C and D) Changes in the CD
spectrum (C) and the mean residue ellipticity (MRE) (D) at 222 nm of 5 μM α-synuclein in the presence of 1.25 mM DOPS:DOPE:DOPC (30:50:20) vesicles in the
absence (black) and presence (colors) of increasing concentrations of squalamine: 10 μM (brown), 20 μM (green), 30 μM (red), 40 μM (orange), 50 μM (violet),
60 μM (blue), and 70 μM (light blue) in 20 mM Tris (pH 7.4) and 100 mM NaCl. The dashed horizontal line in D indicates the MRE at 222 nm of monomeric
α-synuclein in the absence of lipids. Nearly complete displacement of α-synuclein is achieved for a lipid:squalamine ratio of about 18:1. (E) Ratios of the
α-synuclein NMR peak heights as a function of added squalamine for three residues representative of the three regions of α-synuclein with distinct forms of
behavior (11), the N-terminal residue M1 (circles), the central non-Aβ component (NAC) residue G86 (squares), and the C-terminal residue A107 (crosses).
(F) Ratios of the NMR peak heights of 100 μM of α-synuclein observed in 1H-15N NMR HSQC spectra in the presence of DOPE:DOPS:DOPC (30:50:20) vesicles
(1.25 mM) and different concentrations of squalamine (0 μM, circles; 64 μM, squares; 96 μM, triangles; 112 μM, rhomboids; 144 μM, hexagons; and 176 μM,
inverted triangles) relative to peak heights in a spectrum of α-synuclein in the absence of lipids and squalamine. Essentially complete displacement of
α-synuclein from lipid membranes is observed at a concentration of squalamine of ca. 200 μM, corresponding to a lipid:squalamine ratio of about 6:1. For all
the experiments shown in this figure N-terminally acetylated α-synuclein was used (45).
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characterize the displacement of the protein from lipid membranes
by squalamine, as suggested by the CD experiments. This approach
is based on the fact that even very weak interactions typically gen-
erate measurable shifts in the NMR signals of interacting molecules
and often broaden the resonances to an extent that is determined by
the rates involved in the binding process.
We first incubated free monomeric α-synuclein in the absence
of lipids and in the presence of increasing concentrations of
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Fig. 2. Squalamine inhibits α-synuclein aggregation via competitive binding with lipid membranes. (A) Changes in the CD spectrum of 20 μM α-synuclein in the
presence of 1 mM DMPS and in the absence (black) or presence (colors) of increasing concentrations of squalamine: 25 μM (violet), 50 μM (pink), 100 μM (blue),
150 μM (light blue), and 200 μM (aqua). The spectrum of α-synuclein in the absence of both DMPS and squalamine is shown in light green and the CD spectrum of
α-synuclein in the absence of DMPS and the presence of 200 μM squalamine is shown in dark green. Essentially complete displacement of the protein from the
membrane was observed for a squalamine:lipid ratio of about 1:5. (B) Changes in the concentration of α-synuclein bound to DMPS vesicles with increasing
concentrations of squalamine. The data are well described by a competitive binding model with KD,α and Lα [0.5 μM and 30 μM, respectively (12)], and the fit yields
KD,S = 67 nM and LS = 7.3, respectively (see SI Materials and Methods for details). (C) Global fits of the early time points in the kinetic traces of α-synuclein ag-
gregation at increasing concentrations of squalamine. For each dataset, the concentration of DMPS is 100 μM and that of α-synuclein is 20 μM (black), 40 μM (red),
60 μM (yellow), 80 μM (green), and 100 μM (blue). The squalamine concentration used was 0 μM, 1 μM, 2.5 μM, 5 μM, and 10 μM. (D) Changes in thioflavin-T (ThT)
fluorescence when 100 μM α-synuclein was incubated with 100 μM DMPS vesicles in the presence of increasing concentrations of squalamine: 0 μM (black), 1 μM
(yellow), 2.5 μM (orange), 5 μM (red), and 10 μM (brown). All data were acquired under quiescent conditions at 30 °C and duplicate runs are shown. (E) Variation in
the relative rate of lipid-induced aggregation of α-synuclein with increasing concentrations of squalamine (0 μM, black; 1 μM, yellow; 2.5 μM, orange; 5 μM, red;
and 10 μM, brown). The solid line is the corresponding global fit using a competitive binding model (See SI Materials and Methods for details) with only one free
parameter, nb (the reaction order of the lipid-induced aggregation with respect to the fraction of the protein bound), which was found to be 5.5.
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squalamine and observed small chemical shift changes in the
resonances of residues in the C-terminal region of the protein
(Fig. S1), consistent with those associated with the weak binding
of α-synuclein to other polyamine compounds (33). The in-
teraction involves two regions between residues 85 and 140, where
the NMR spectra reveal two distinct types of behavior; the
resonances of residues 88–106 show only very small effects, but
those of residues 113–139 are affected in a much more pro-
nounced manner. To probe the stoichiometry of the interaction
of α-synuclein and squalamine and to estimate the binding
constant, we performed a series of dilutions on a sample con-
taining 80 μM α-synuclein and 240 μM squalamine, monitoring
the intensities of the α-synuclein resonances (Fig. S1). This
experiment shows that when the squalamine concentration
becomes lower than about 100 μM, the spectral changes char-
acteristic of the interaction are no longer visible.
Then, we investigated further the displacement of α-synuclein
from the membrane by squalamine. It has been previously
demonstrated that addition of DOPE:DOPS:DOPC (50:30:20)
vesicles to a sample of α-synuclein results in attenuation of
the main-chain amide signals of its about 100 N-terminal resi-
dues in the 1H-15N heteronuclear single quantum correlation
(HSQC) NMR spectrum (27). This attenuation is attributable to
the binding of these residues to the large, slowly tumbling vesi-
cles, whereas the secondary structure becomes α-helical, as in-
dicated by CD measurements and by indirect transferred nuclear
Overhauser effects (NOEs) in the spectra (27). By contrast, the
resonances of the 40 C-terminal residues retain almost their full
intensity and experience only very minor changes in chemical shifts
(Fig. 1F). In the present work we prepared an NMR sample
containing a sufficient quantity of lipid vesicles to cause a large
attenuation of the signals of α-synuclein and then titrated in-
creasing amounts of squalamine into the sample (Fig. 1 E and F).
We observed that the addition of about 200 μM of squalamine
resulted in an almost complete recovery of the intensity of the
α-synuclein signals (Fig. 1F) and found that signals from residues
101–120, which are affected to a much smaller extent than residues
1–100 by the presence of lipids, were restored to their free in-
tensities at a much lower concentration of squalamine.
Interestingly, even though the squalamine:α-synuclein ratios
and the absolute squalamine concentrations in the presence of
DOPE:DOPS:DOPC vesicles (Fig. 1 C and D) were comparable
to those in the lipid-free experiments (Fig. S1), there was no
evidence in the former experiments for the interaction of
squalamine with the C-terminal residues. In addition, when the
squalamine concentration was increased to 80 μM in the absence
Fig. 3. Squalamine suppresses the toxicity of α-synuclein oligomers in human neuroblastoma cells by inhibiting their binding to the cell membranes.
(A) Effects of squalamine on α-synuclein oligomer-induced MTT reduction in SH-SY5Y cells. α-Synuclein oligomers (23, 24) were resuspended in the cell culture
medium at a concentration of 0.3 μM, incubated with or without increasing concentrations (0.03 μM, 0.1 μM, 0.3 μM, 1.0 μM, and 3.0 μM) of squalamine for 1 h
at 37 °C under shaking conditions, and then added to the cell culture medium of SH-SY5Y cells for 24 h. The cells were also treated with squalamine pre-
incubated in the absence of oligomers for 1 h at 37 °C under shaking conditions. **P ≤ 0.01 and ***P ≤ 0.001, respectively, relative to untreated cells and °°P ≤
0.01 relative to cells treated with α-synuclein oligomers. (B) Representative confocal scanning microscope images of SH-SY5Y cells showing the effect of
squalamine on α-synuclein oligomer-induced ROS production. α-Synuclein oligomers were resuspended in the cell culture medium at a concentration of
0.3 μM, incubated with or without increasing concentrations (0.03 μM, 0.3 μM, and 3.0 μM) of squalamine for 1 h at 37 °C under shaking conditions, and then
added to the cell culture medium of SH-SY5Y cells for 15 min. The cells were also treated with 3 μM squalamine preincubated without oligomers for 1 h at
37 °C while shaking. The green fluorescence arises from the 2′,7′-dichlorodihydrofluorescein diacetate (CM-H2DCFDA) probe that has reacted with ROS. (Scale
bar, 30 μm.) *P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001, respectively, relative to untreated cells. °°P ≤ 0.01 and °°°P ≤ 0.001, respectively, relative to untreated cells
and the symbol °° indicates P ≤ 0.01 relative to cells treated with α-synuclein oligomers. (C) Representative confocal scanning microscopy images of the apical
sections of SH-SY5Y cells treated for 15 min with α-synuclein oligomers (0.3 μM) and increasing concentrations (0.03 μM, 0.1 μM, 0.3 μM, 1.0 μM, and 3.0 μM) of
squalamine. Red and green fluorescence indicates the cell membranes and the α-synuclein oligomers, respectively. (Scale bar, 10 μm.)
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of α-synuclein, the sample became highly opaque, suggesting that
the lipid vesicles in the sample undergo fusion within seconds, an
effect likely to be due to the change in the electrostatic prop-
erties of the lipid vesicles upon squalamine binding. However, in
the presence of α-synuclein the samples were stable and no
precipitation occurred within the time scales of either the CD or
the NMR experiments.
Taken together, these observations demonstrate that, in a sys-
tem containing α-synuclein and negatively charged lipid mem-
branes, squalamine partitions to the membrane surface, thereby
inducing the displacement of the protein from the membrane
rather than remaining free in solution and interacting directly
with α-synuclein.
Squalamine Inhibits Lipid-Induced Aggregation of α-Synuclein by
Competing for Binding Sites at the Surface of the DMPS Vesicles. In
the light of these results, we explored the effects of squalamine
on the binding and aggregation of α-synuclein in the presence of
1,2-dimyristoyl-sn-glycero-3-phospho-L-serine (DMPS)-containing
vesicles, which have been shown to be particularly effective in
enhancing the rate of aggregation and amyloid formation by
α-synuclein (12). We first incubated the protein under conditions
where effectively all of the α-synuclein molecules present in the
sample were bound to the vesicles and in the presence of increasing
concentrations of squalamine. As observed in the experiments with
the DOPS:DOPE:DOPC (30:50:20) vesicles (Fig. 1 C–F), the
presence of squalamine progressively decreased the α-helical con-
tent of α-synuclein (Fig. 2A), again indicating that squalamine dis-
places the protein from the vesicles. We thus used the same
competitive binding model (Fig. 2B) as the one describing the dis-
placement of α-synuclein from the vesicle by β-synuclein (22), where
both α-synuclein and squalamine compete for binding sites at the
surface of the DMPS vesicles, in order to analyze the CD data. This
model, together with previously determined binding constants for
the α-synuclein/DMPS system (12), described the data very closely
and yielded values for both the binding constant and the stoichio-
metry of the binding of squalamine to DMPS vesicles, KD,  S = 67 nM
and LS = 7.3, respectively. These results suggest that the positively
charged squalamine binds strongly to the anionic head groups of
the lipid bilayers, progressively coating the surfaces of the lipid
membrane, thereby decreasing the electrostatic forces and com-
peting for the sites on the lipid vesicles that are required for the
binding of α-synuclein.
We further monitored the effects of increasing concentrations
of squalamine on the size and the fluidity of the DMPS vesicles,
using dynamic light scattering and differential scanning calorime-
try (Fig. S2), respectively. The presence of squalamine caused an
increase in the diameter of the DMPS vesicles from about 20 nm
to values in excess of 100 nm at squalamine:lipid ratios greater
than 0.1 (Fig. S2). In addition, differential scanning calorimetry
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(DSC) traces of the DMPS vesicles in the absence and presence of
50 μM squalamine show that the molecule induced a decrease in
the melting temperature by 10 °C (Fig. S2), an effect similar to
that observed upon binding of α-synuclein to DMPS vesicles (12),
suggesting that squalamine interacts with the membrane surface.
Overall, however, these results indicate that at squalamine:DMPS
ratios below 1:10 the integrity of the vesicles is not compromised.
We then studied the aggregation of α-synuclein in the pres-
ence of DMPS vesicles and increasing concentrations of
squalamine and observed that the overall rate of amyloid for-
mation under such conditions decreases dramatically in a dose-
dependent manner (Fig. 2 C–E). It is interesting to note that
the observed change in the rate of lipid-induced aggregation of
α-synuclein is not likely to be due to a change in the vesicle
morphology; as discussed above, at the squalamine:lipid ratios
used here the diameter of the vesicles ranges from 20 nm to 100 nm
(Fig. S2), and this size variation has been shown not to affect sig-
nificantly the kinetics of amyloid formation by α-synuclein in the
presence of DMPS vesicles (12).
To quantify further the effects of squalamine on α-synuclein
aggregation, we analyzed the early stages of the kinetic traces
(Fig. 2C) (12) (see SI Materials and Methods for details) and
determined the rate of α-synuclein aggregation at each concentra-
tion of squalamine (Fig. 2E). The change in the relative rate of
lipid-induced aggregation of α-synuclein with increasing concen-
tration of squalamine is well described by a competitive binding
model, with the binding constants determined here for squalamine
(KD,S and LS) and previously for α-synuclein (KD,α and Lα) (12).
Taken together, these results are consistent with the conclusion that
squalamine inhibits the lipid-induced aggregation of α-synuclein via
competitive binding at the surfaces of the vesicles, as observed for
β-synuclein (22). In addition, we probed the interaction of
squalamine with α-synuclein fibrils by incubating squalamine in
the presence of the fibrils. We then centrifuged the sample and
separated the supernatant from the pellet. Then we assessed
the quantity of squalamine in the supernatant before and after
incubation with fibrils using, mass spectrometry (Fig. S3). We
found that, after incubation, the signal corresponding to
squalamine in the supernatant was reduced (−85%), suggesting
a degree of binding to α-synuclein fibrils. This interaction may also
play a role in the observed inhibition of squalamine on the lipid-
induced aggregation of α-synuclein. As a control we performed
the same experiment, using Aβ42 fibrils (Fig. S3). In this case, we
observed a lower binding signal (−66%), indicating stronger
binding to α-synuclein fibrils.
Squalamine Suppresses the Toxicity of α-Synuclein Oligomers in
Human Neuroblastoma Cell Lines by Inhibiting Their Binding to
Cellular Membranes. We have recently developed a protocol to iso-
late oligomers of α-synuclein shown to be toxic to human cells (23,
24). We exposed cultured human SH-SY5Y neuroblastoma culture
cells to such oligomers at a concentration of 0.3 μM (monomer
equivalent of α-synuclein). Under these conditions, the oligomers
were indeed toxic to the cells, as demonstrated by the decreased
ability of the cells to chemically reduce 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Fig. 3A). The
cells were also treated with α-synuclein oligomers (0.3 μM) in
the presence of increasing concentrations of squalamine (up to
3.0 μM) (Fig. 3A). The results show that squalamine decreases
markedly the mitochondrial damage induced by the α-synuclein
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oligomers, as indicated by MTT reduction data, with the pro-
tective effect increasing with squalamine concentration (Fig. 3A).
Similar results were obtained from analyzing intracellular re-
active oxygen species (ROS) production within SH-SY5Y cells;
the α-synuclein oligomers (0.3 μM) induced a sharp increase in
ROS levels in this cell model, indicating increased ROS-induced
cellular damage (Fig. 3B). Upon treatment of the cells with
α-synuclein oligomers (0.3 μMmonomer equivalent) and increasing
concentrations (0.03 μM, 0.3 μM, and 3 μM) of squalamine, the
degree of ROS-derived fluorescence was observed to decrease
steadily with increasing squalamine concentration (Fig. 3B), and
at the highest ratio of squalamine:α-synuclein concentrations it
was found to suppress almost completely the increase of in-
tracellular ROS levels caused by the oligomers.
We then investigated the mechanism by which squalamine
inhibits α-synuclein oligomer toxicity by analyzing the interac-
tions between the oligomers (0.3 μM) and human SH-SY5Y
neuroblastoma cells at increasing concentrations (up to 3.0 μM)
of squalamine, using confocal microscopy and anti–α-synuclein
antibodies. The images were scanned at apical planes to detect
oligomers (green channel) interacting with the cellular surface
(red channel) (Fig. 3C). Large numbers of α-synuclein oligomers
bound to the plasma membrane were observed in cells exposed
to oligomers, but their number was markedly decreased as the
squalamine concentration was increased (Fig. 3C). As we have
shown previously, the toxicity caused by protein oligomers can be
correlated with membrane binding (34) and this finding provides
an explanation for the inhibition of the cellular damage induced
by α-synuclein oligomers by squalamine and is consistent with a
competitive binding model.
Squalamine Reduces α-Synuclein Aggregation and Related Paralysis in
a Worm Model of PD. We extended our in vitro observations that
squalamine can suppress the aggregation and toxicity of α-synuclein
to a living system. We used a well-studied model of PD in the
nematode worm C. elegans, which is based on the overexpression
of α-synuclein tagged with yellow fluorescent protein (YFP) in the
muscle cells of the nematode worms (25). This model organism, in
which the presence of α-synuclein causes characteristic phenotypic
changes (25), has been successfully used to probe the nature of a
range of neurodegenerative conditions and has been used in high-
throughput screens to identify novel genes that modify the course
of disease (35, 36).
Motility in C. elegans declines during aging and it can be
measured in liquid media by counting the number of body bends
per unit of time (37). This phenotypic readout has been used
extensively for identification of genes and pathways connected to
age-related protein homeostasis, as well as for the definition of
modifiers of protein aggregation (25, 35, 36); both of these
processes are closely associated with the onset and development
of neurodegenerative diseases (5, 7, 38). We first tested different
approaches to optimize the effects of squalamine in vivo and
found that the best treatment regime was to administer the
compound at the larval stage L4, when the worms were fully
developed, and to maintain the worms on plates seeded with
squalamine for their whole lifespan. By carrying out standard
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body bend assays (37), we observed a very significantly im-
proved motility of the PD worms treated with squalamine (Fig.
S4). By contrast, the motility of a C. elegans strain expressing
only YFP, used here as a control, was not detectably affected by
squalamine (Fig. S4).
As standard body bend assays monitored by manual means can
be prone to errors and are not always reproducible, many digital
tracking platforms have recently been proposed to characterize
worm behavior in a more quantitative and rigorous way (39). To
improve the reproducibility of the results, we have developed a
high-throughput microscopic screening procedure that allows robust
C. elegans phenotypic screening with improved statistics, coupled
with automated analysis of the motility of the animals (see SI Ma-
terials and Methods for details).
Movies of swimming worms were recorded using a high-per-
formance imaging lens and a machine vision camera at a high
number of frames per second (fps) for 30 s or 1 min, and the
platform enabled us to image simultaneously up to 200 swimming
animals over the whole surface of a 6-cm agar plate (see SI Ma-
terials and Methods for details). Using this method, we confirmed
with statistical confidence the observed improved motility (Fig. S5)
of the PD worms upon squalamine administration (Figs. 4A, 5, and
6 and Movies S1–S4). Automated analysis of the velocities of the
movements of the worms further confirmed a significant difference
between treated and untreated PD worms, and indeed those ani-
mals exposed to 50 μM squalamine showed motility levels that
were essentially the same as those of the control worms (Fig. 4B).
We then explored the effects of squalamine on the aggregation
of α-synuclein in PD worms by fluorescence microscopy. Fol-
lowing the addition of squalamine to the medium in which the
animals were maintained, we observed a substantial decrease in
α-synuclein inclusion formation in aged PD worms (day 12 of
adulthood) (Fig. 4 C and D), despite the fact that the levels of
α-synuclein expression in the PD worms in the absence and in the
presence of squalamine were found to be closely similar (Fig.
4E). We also demonstrated that no effects could be detected on
the intensity or the distribution pattern of YFP expressed within
the body-wall muscle of the control worms (Fig. 4C).
Furthermore the protective effect of squalamine was apparent
throughout the study, as shown by recovery of motility (thrashing
and speed), decrease in paralysis rate, and the decrease in the
number of inclusions (Fig. 5). Finally, to assess whether or not
the observed effects of squalamine in suppressing inclusion for-
mation and toxicity were specific to the α-synuclein worms, we
tested squalamine in a worm model of Aβ42-mediated dysfunction
(40). In this system, where the presence of lipids is not required for
the initiation of Aβ42 aggregation (41, 42), we observed that
squalamine, at concentrations that completely restored the
pathological phenotype in the Abeta42 worms, showed no sig-
nificant protective effects (Fig. S5), thereby indicating the
specificity of squalamine against α-synuclein aggregation.
Discussion
We have shown by using a variety of biophysical techniques that
squalamine can inhibit in vitro the aggregation of α-synuclein
induced by lipid membranes. Furthermore we have shown by
using a cellular model and an animal model of PD that squal-
amine dramatically reduces in vivo the toxicity associated with
α-synuclein aggregation (Fig. 6).
To study the binding of α-synuclein to lipids, we first used SUVs
composed of DOPS, DOPE, and DOPC, which are the most
abundant lipids found in the membranes of synaptic vesicles (26).
Titrating squalamine into a solution of α-synuclein bound to SUVs
caused the α-helical content of α-synuclein to decrease in an ap-
proximately linear manner with squalamine concentration, as
measured by CD and NMR, thus suggesting that squalamine dis-
places α-synuclein from lipid membranes, as observed for a range of
other protein/lipid systems (17). We further explored the effects of
squalamine on the binding and aggregation of α-synuclein in the
presence of DMPS-containing vesicles, which have been shown to
be particularly effective in enhancing the rate of aggregation and
amyloid formation of α-synuclein (12). The presence of squalamine
progressively decreased the α-helical content of α-synuclein, again
indicating that this compound displaces the protein from the vesi-
cles, as recently observed for β-synuclein (22). To analyze these
data, we thus used the same competitive binding model as the one
describing the inhibitory effect of β-synculein on α-synuclein lipid-
induced aggregation (22), where both α-synuclein and squalamine
compete for binding sites at the surface of the DMPS vesicles,
which validated the model in a quantitative manner.
In addition, we have shown that squalamine does not interact
directly with monomeric α-synuclein in free solution, except at
very high concentrations and in the absence of lipids, and that it
affects the size and the thermotropic properties of lipid vesicles
only at high squalamine:DMPS ratios (>0.1). Moreover, we have
observed that the overall rate of lipid-induced α-synuclein ag-
gregation in vitro decreases dramatically and in a dose-de-
pendent manner upon incubation with squalamine.
We then extended this study by using SH-SY5Y cells treated
with oligomers of α-synuclein previously shown to be toxic to
cells in culture (23, 24) and found that squalamine inhibits
completely the mitochondrial dysfunction and the cellular ROS
production induced by the oligomers. The degree of binding of
toxic α-synuclein oligomers to neuronal cells also decreased with
increasing squalamine concentration, and based on our results,
we proposed a competitive binding model, where toxic oligomers
of α-synuclein and squalamine compete for binding sites at the
surface of neuronal cells. These results suggest that squalamine
drastically decreases not only the neurotoxicity caused by the
intracellular accumulation of α-synuclein aggregates but also
the cellular damage induced by aggregates interacting with the
membrane of neuronal cells. We then provided further evidence
for a protective effect of squalamine observed in vitro and in
cells by using a well-studied C. elegans model of PD (25). When
worms were exposed to squalamine from an early stage in their
development, we observed an almost complete recovery of the
motility dysfunction induced by α-synuclein together with a
substantial decrease in inclusion formation in treated PD worms.
Taken together, these results suggest that squalamine inhibits the
initial step in the lipid-induced aggregation of α-synuclein through
competitive binding at the surface of the lipid vesicles and also
drastically reduces the toxicity of oligomeric forms of α-synuclein in
vivo. We note that it is also possible that other secondary mecha-
nisms of action, such as direct interactions with fibrils, may be
present and could work in synergy with the principal mechanism of
action of squalamine that we have described.
Conclusions
We have shown that in vitro and in cell cultures squalamine sup-
presses the initial events in the aggregation of α-synuclein by dis-
placing the protein from lipid membranes, where such events
preferentially take place, and also acts to reduce the interactions of
oligomeric aggregates with the membrane surfaces (Fig. 6). These
results indicate the mechanisms by which squalamine significantly
inhibits the aggregation of α-synuclein in vivo and also reduces
dramatically its associated toxicity. We suggest, therefore, that
squalamine, and by extension other molecules that can compete ef-
fectively with α-synuclein for lipid membrane binding, could have the
potential to act as therapeutic agents for PD and other conditions
associated with the pathogenic aggregation of α-synuclein.
Materials and Methods
Extended experimental procedures are described in SI Materials and Methods.
Wild-type α-synuclein was expressed in Escherichia coli and purified as pre-
viously described (10). DOPE/DOPS/DOPC vesicles were prepared as previously
described (27). DMPS vesicles were prepared as previously reported (12) and
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aggregation kinetics and related data analysis were carried out as previously
described (12). α-Synuclein oligomers were also prepared as described
previously (23, 24) and cell cytotoxicity assays were carried out as indicated
(43). In vivo experiments were carried out by using a well-studied C. elegans
model of PD (25).
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SI Materials and Methods
Squalamine. Squalamine (as the dilactate salt) was synthesized as
previously described (49) and was greater than 97% pure.
Experiments with DOPS:DOPE:DOPC Vesicles.
Protein expression and purification. N-terminally acetylated α-synu-
clein, which is the most prevalent form of α-synuclein in mam-
malian cells and also increases membrane affinity (45–47), was
obtained as previously described (45). Briefly, N-terminal acet-
ylation of WT α-synuclein was achieved by coexpression of a
plasmid carrying the components of the NatB complex with a
plasmid containing the wild-type α-synuclein gene, following the
protocol described previously (48). We observed that the re-
strictive conditions of M9 media have a strong effect on the
acetylation reaction. Essentially complete acetylation (≥98%)
was observed only when using protonated M9 medium, supple-
mented with 1 g/L protonated IsoGro (Sigma). Unless noted
otherwise, all NMR experiments with acetylated α-synuclein
were performed on 15N- and 13C-labeled α-synuclein samples,
obtained using [15N,13C] IsoGro.
Preparation of vesicles. Phospholipids were purchased from Avanti
Polar Lipids as a lyophilized powder of a DOPE/DOPS/DOPC
mixture with a 5:3:2 weight ratio (coagulation reagent I). Vesicles
were prepared as described previously (27) in 20 mM imidazole
buffer [pH 6, 10% (wt/vol)].
NMR spectroscopy. NMR experiments were performed using a
600-MHz Bruker spectrometer equipped with a cryoprobe.
The sample temperature was set to 288 K, and the sample buffer
composition was 20 mM imidazole, 100 mM NaCl, pH 6.
Squalamine is highly soluble in distilled water, but its solubility
in 20 mM imidazole, 100 mM NaCl is reduced to ca. 130 μM.
Concentrations above this level result in NMR-invisible, light-
scattering aggregates. The solubility in PBS (pH 7.4) solution
was measured at ca. 35 μM.
CD Spectroscopy. All CD measurements were taken at 20 °C,
using a 1-mm path-length cuvette. Samples contained 20 mM
Tris (pH 7.4), 100 mM NaCl, 5 μM N-terminally acetylated
α-synuclein, and 0.1% wt/vol lipid vesicles (ca. 1.25 mM).
The vesicles consisted of 30% DOPS, 50% DOPE, and 20%
DOPC.
Experiments with DMPS Vesicles.
Reagents. Sodium salt (DMPS) was purchased from Avanti Polar
Lipids. Sodium phosphate monobasic (NaH2PO4; BioPerformance
certified, ≥99.0%), sodium phosphate dibasic (Na2HPO4; Reagent-
Plus, ≥99.0%), sodium chloride (NaCl; BioXtra, ≥99.5%), and
sodium azide (NaN3; ReagentPlus, ≥99.5%) were purchased
from Sigma Aldrich. ThT UltraPure Grade (≥95%) was pur-
chased from Eurogentec.
Protein expression and lipid preparation.WT (nonacetylated) α-synuclein
was expressed in E. coli and purified as previously described
(10, 50). The lipids were dissolved in 20 mM phosphate buffer
(NaH2PO4/Na2HPO4) (pH 6.5), 0.01% NaN3 and stirred at
45 °C for 2 h. The solution was then frozen and thawed five
times, using dry ice and a water bath at 45 °C. The preparation of
vesicles was carried out using sonication (Bandelin Sonopuls HD
2070, 3 × 5 min, 50% cycles, 10% maximum power) on ice. After
centrifugation, the sizes of the vesicles were checked using dy-
namic light scattering (Zetasizer Nano ZSP; Malvern Instru-
ments) and were shown to consist of a distribution centered at a
diameter of 20 nm.
CD spectroscopy.
Data acquisition. CD samples were prepared as previously de-
scribed (12) by incubating 20 μM α-synuclein in the presence of
1 mMDMPS vesicles in 20 mM phosphate buffer (pH 6.5), 0.01%
NaN3, and increasing concentrations of squalamine. A squal-
amine stock solution was prepared by dissolving the molecule
in doubly distilled water to a final concentration of 5 mM.
Far-UV CD spectra were recorded on a JASCO J-810 in-
strument equipped with a Peltier thermally controlled cuvette
holder at 30 °C. Quartz cuvettes with path lengths of 1 mm
were used, and CD spectra were obtained by averaging five
individual spectra recorded between 250 nm and 200 nm with a
bandwidth of 1 nm, a data pitch of 0.2 nm, a scanning speed of
50 nm/min, and a response time of 1 s. Each value of the CD
signal intensity reported at 222 nm corresponds to the average
of three measurements, each acquired for 10 s. For each
protein sample, the CD signal of the buffer used to solubilize
the protein was recorded and subtracted from the CD signal of
the protein.
Data analysis. The change in the concentration of α-synuclein
bound to the DMPS vesicles with increasing concentration of
squalamine was fitted to the same competitive binding model
as the one described for the competitive binding of α-synu-
clein and β-synuclein to DMPS vesicles (22), taking into ac-
count the different stoichiometries in which DMPS binds to
α-synuclein and squalamine. The equations for the binding
equilibria are
KD,α =

DMPSf

αf

Lα½αb [S1]
KD,S =

DMPSf

Sf

LS½Sb , [S2]
where KD,α and KD,S are the binding constants of α-synuclein and
squalamine, respectively; ½αf  and ½αb are the concentrations of
free and bound α-synuclein; ½Sf  and ½Sb are the concentrations
of free and bound squalamine; ½DMPSf  is the concentration of
free DMPS; and Lα and LS denote the stoichiometries in which
DMPS binds to α-synuclein and squalamine, i.e., the number of
molecule of DMPS interacting with one molecule of either
α-synuclein or squalamine, respectively.
By using the mass conservation equations,
½α= ½αb+

αf

[S3]
½S= ½Sb+

Sf

[S4]
½DMPS= DMPSf +LS½Sb+Lα½αb, [S5]
where ½α, ½S, and ½DMPS are the total concentrations of
α-synuclein, squalamine, and DMPS, respectively. An expres-
sion for ½αb in terms of KD,α, KD,S, Lα, LS, ½α, ½S, and ½DMPS
can be derived. This is the standard solution of the cubic
equation:
KD,α =
ð½DMPS−LS½Sb−Lα½αbÞð½α− ½αbÞ
Lα½αb [S6]
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½Sb= ½DMPS−Lα½αb+KD,SLS +LS½S2LS −
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4LSð½αbLα½S−½DMPS½SÞ+
½DMPS−½αbLα+KD,SLS+LS½S2q
2LS
.
[S7]
Its solution is not shown here due to its length. For each data
point, the concentrations ½αb, ½S, and ½DMPS are known, and
the equilibrium constant and stoichiometry for the α-synuclein/
DMPS system, KD,α and Lα, were set to the values determined
previously (12). The variation of ½αb at a fixed [DMPS] (1 mM)
and ½α (20 μM), with increasing ½S, was fitted using the resulting
equation with two unknowns, KD,S and LS, and the best fit is
obtained for KD,S = 67 nM and LS = 7.4 (Fig. 3B).
Aggregation kinetics.
Sample preparation and data acquisition. α-Synuclein was in-
cubated in 20 mM sodium phosphate (pH 6.5), 0.01% NaN3, in
the presence of 50 μM ultrapure ThT, 100 μM DMPS vesicles,
and increasing concentrations of squalamine (0–10 μM). The
stock solution of squalamine was prepared by dissolving the
molecule in 20 mM phosphate buffer to a final concentration of
100 μM. The change in the ThT fluorescence signal with time
was monitored using a plate reader (BMG Labtech) under qui-
escent conditions at 30 °C. Corning 96-well plates with half-area
(black/clear bottom polystyrene) nonbinding surfaces were used
for each experiment. The data were then analyzed as described
previously (12).
Data analysis.To determine the rate of lipid-induced aggregation
of α-synuclein at different squalamine concentrations, we used
the same model as the one describing the inhibition of α-synu-
clein lipid-induced aggregation by β-synuclein (22): The rate
depends on the fractional coverage of a lipid vesicle in α-synu-
clein (θα) and we define nb as the reaction order with respect to
θα. We can adapt the equations given in ref. 12 to reflect this,
MðtÞ=KMk+mð0Þ
n+1kn½DMPSθnbα t2
2ðKM +mð0ÞÞLα [S8]
where t is the time, MðtÞ is the aggregate mass, mð0Þ is the free
monomer concentration, KM is the saturation constant of the
elongation process, kn and k+ are the rate constants of nucleation
and elongation, respectively, and ½DMPSLα is the concentration of
protein-binding sites at the surface of the membrane. We initially
used Eq. S8 to fit the early times of the kinetic traces measured
for α-synuclein in the presence of 100 μM DMPS and in the
absence of squalamine (where θα = 1 as we are in a regime where
the vesicles are saturated), with KM , knk+, and n being global
fitting parameters (fit, Fig. 3B). The global fit yields n = 0.624,
KM = 54 μM, and knk+ = 9.9 × 10−3 M−(n+1) s−2. The values
obtained for these three parameters were then used as inputs into
the fitting of the data in the presence of squalamine. The assump-
tion that the presence of squalamine merely alters the fraction of
α-synuclein bound but does not affect any of the other rates is
implicit. We then fitted the data in the presence of squalamine,
with all parameters fixed to their values in the absence of squal-
amine, with the exception of θnbα . All fits were within error of the
experimental data. This way we obtain θnbα at all α-synuclein and
squalamine concentrations.
We then used a simplified competitive binding model to an-
alyze the change of θnbα with changing squalamine:α-synuclein
ratios, to determine nb. In the competitive binding model de-
scribed above, the solution to Eq. S6 simplifies when all binding
sites on the vesicles can be assumed to be occupied, as is the
case in the kinetic experiments. In this case Eq. S5 becomes
½DMPS≈LS½Sb+Lα½αb. The concentration of bound α-synu-
clein is then simply given by
½αb= ½DMPSLακ− ½DMPSLS − ½αLαLS −LαLS½Sκ
2

L2ακ−LαLS
 +
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
4½α½DMPSLS

L2ακ−LαLS

+
 ½DMPSLS + ½αLαLS −
½DMPSLακ+LαLS½Sκ
2s
2

L2ακ−LαLS
 ,
[S9]
where κ= KD,αKD,S. The global fits of θ
nb
α =
	
½αb Lα
½DMPS

nb
agree well with
the data (Fig. 3D) and we obtain nb = 5.5.
Mass Spectrometry Experiments on α-Synuclein and Aβ Fibrils.
Preparation of fibrils. α-Synuclein fibrils were prepared as described
previously (10, 51). Briefly, a 500-μL sample of α-synuclein at a
concentration of 600 μM was incubated in 20 mM phosphate
buffer (pH 6.5) for 72 h at about 40 °C and stirred at 1,500 rpm
with a Teflon bar on an RCT Basic Heat Plate (IKA). Fibrils
were diluted to a monomer equivalent concentration of 200 μM,
divided into aliquots, flash frozen in liquid N2, and stored at
−80 °C for experiments. For experiments with the Aβ peptide (in
this work we used the 42-residue form), fibrils were prepared as
described previously (13). Briefly, Aβ monomer at a concentra-
tion of 78 μL was incubated in 20 mM phosphate buffer (pH 8)
with 200 μM EDTA, 0.02% NaN3, for 6 h at about 37 °C. Before
mass spectrometry analysis, 78 μM of equivalent α-synuclein and
Aβ fibrils was centrifuged at 100,000 × g for 1 h at the ultra-
centrifuge. The pellet was then resuspended in the same volume
of Tris buffer for further analysis.
Preparation of samples for mass spectrometry experiments. Fibrils of
α-synuclein or Aβ at a concentration of 10 μM were incubated
with 10 μM squalamine in 20 mM Tris (pH 7.4), 100 mM NaCl
overnight under quiescent conditions at room temperature. The
samples were afterward centrifuged at 100,000 × g for 30 min at
the ultracentrifuge. The supernatant was then removed for
analysis. In the present work the experiments were run using a
Waters Corporation Xevo G2-S QTOF.
Experiments on Human SH-SY5Y Neuroblastoma Cells.
Preparation of oligomers. Samples enriched in oligomeric α-synu-
clein species were prepared as previously described (34). Briefly,
monomeric α-synuclein was lyophilized in Milli-Q water and
subsequently resuspended in PBS, pH 7.4, to give a final con-
centration of ca. 800 μM (12 mg/mL). The resulting solution was
passed through a 0.22-μm cutoff filter before incubation at 37 °C
for 20–24 h under quiescent conditions. Very small amounts of
fibrillar species formed during this time were removed by ul-
tracentrifugation for 1 h at 90,000 rpm (using a TLA-120.2
Beckman rotor, 288,000 × g). The excess monomeric protein and
some small oligomers were then removed by multiple filtration
steps, using 100-kDa cutoff membranes. The final concentration
of oligomers was estimated based on the absorbance at 275 nm,
using a molar extinction coefficient of 5,600 M−1·cm−1.
Neuroblastoma cell culture. Human SH-SY5Y neuroblastoma cells
(A.T.C.C.) were cultured in DMEM, F-12 HAM with 25 mM
Hepes and NaHCO3 (1:1) and supplemented with 10% FBS,
1 mM glutamine, and 1.0% antibiotics. Cell cultures were main-
tained in a 5% CO2 humidified atmosphere at 37 °C and
grown until they reached 80% confluence for a maximum of 20
passages (24).
MTT reduction assay. α-Synuclein oligomers (24) (0.3 μM) were
incubated with or without increasing concentrations (0.03 μM,
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0.1 μM, 0.3 μM, 1 μM, and 3 μM) of squalamine for 1 h at 37 °C
under shaking conditions and then added to the cell culture
medium of SH-SY5Y cells seeded in 96-well plates for 24 h. The
protein:squalamine molar ratios used here were 10:1, 3:1, 1:1,
1:3, and 1:10. The MTT reduction assay was performed as pre-
viously described (43).
Measurement of intracellular ROS. α-Synuclein oligomers (0.3 μM)
were preincubated for 1 h with or without increasing concen-
trations (0.03 μM, 0.3 μM, and 3 μM) of squalamine for 1 h at
37 °C under shaking and then added to the cell culture medium
of SH-SY5Y cells seeded on glass coverslips for 15 min. To
detect intracellular ROS production, cells were then loaded with
10 μM CM-H2DCFDA (Life Technologies) as previously de-
scribed (43). Cell fluorescence was analyzed by a TCS SP5
scanning confocal microscopy system (Leica Microsystems)
equipped with an argon laser source, using the 488-nm excitation
line. A series of 1.0-μm-thick optical sections (1,024 × 1,024
pixels) was taken through the cells for each sample, using a Leica
Plan Apo 63 oil immersion objective, and then projected as a
single composite image by superimposition. The confocal mi-
croscope was set at optimal acquisition conditions, e.g., pinhole
diameters, detector gain, and laser powers. Settings were main-
tained constant for each analysis.
Oligomer binding to the cellular membrane. SH-SY5Y cells were
seeded on glass coverslips and treated for 15 min with α-synuclein
oligomers (0.3 μM) and increasing concentrations (0.03 μM,
0.1 μM, 0.3 μM, 1 μM, and 3 μM) of squalamine. After in-
cubation, the cells were washed with PBS and counterstained
with 5.0 μg/mL Alexa Fluor 633-conjugated wheat-germ agglu-
tinin (Life Technologies). After washing with PBS, the presence
of oligomers was detected with 1:250 diluted rabbit polyclonal
anti–α-synuclein antibodies (Abcam) and subsequently with
1:1,000 diluted Alexa Fluor 488-conjugated anti-rabbit secondary
antibodies (Life Technologies). Fluorescence emission was de-
tected after double excitation at 488 nm and 633 nm by the
scanning confocal microscopy system described above and three
apical sections were projected as a single composite image by
superimposition.
C. elegans Experiments.
Media. Standard conditions were used for the propagation of C.
elegans (52). Briefly, the animals were synchronized by hypo-
chlorite bleaching, hatched overnight in M9 (3 g/L KH2PO4,
6 g/L Na2HPO4, 5 g/L NaCl, 1 M MgSO4) buffer, and sub-
sequently cultured at 20 °C on nematode growth medium (NGM)
[1 mMCaCl2, 1 mMMgSO4, 5 μg/mL cholesterol, 250 M KH2PO4
(pH 6), 17 g/L Agar, 3 g/L NaCl, 7.5 g/L casein] plates seeded with
the E. coli strain OP50. Saturated cultures of OP50 were grown
by inoculating 50 mL of LB medium (10 g/L tryptone, 10 g/L
NaCl, 5 g/L yeast extract ) with OP50 and incubating the cul-
ture for 16 h at 37 °C. NGM plates were seeded with bacteria by
adding 350 μL of saturated OP50 to each plate and leaving the
plates at 20 °C for 2–3 d. On day 3 after synchronization, the
animals were placed on NGM plates containing 5-fluoro-2′
deoxy-uridine (FUDR) (75 μM, unless stated otherwise) to inhibit
the growth of offspring.
Strains.The following strains were used. zgIs15 [P(unc-54):: αsyn::
YFP]IV (OW40): In OW40, α-synuclein fused to YFP relocates
to inclusions, which are visible as early as day 2 after hatching
and increase in number and size during the aging of the animals,
up to late adulthood (day 17) (25). rmIs126 [P(unc-54)Q0::YFP]V
(OW450): In OW450, YFP alone is expressed and remains
diffusely localized throughout aging (25). dvIs2 [pCL12(unc-54/
human Aβ 1–42 peptide minigene) + pRF4]: Where Aβ42 ag-
gregates giving rise to adult onset paralysis and egg-laying,
deficiency is observed when the temperature is raised to 20 °C.
Squalamine administration. Aliquots of NGM media containing
FUDR (75 μM) were autoclaved, poured, seeded with 350 μL
OP50 culture, and grown overnight. After incubating for up to
3 d at room temperature, 2.2-mL aliquots of squalamine dis-
solved in water at different concentrations were spotted atop the
NGM plates. The plates were then placed in a sterile laminar
flow hood at room temperature to dry. We first observed that the
compound was toxic when administered to the worms from L1
larval stage (25% worm death), probably due to the high mem-
brane permeability of the worms in this stage. For the final ex-
periments, worms were transferred onto the squalamine-seeded
plates directly at larval stage L4 and they were exposed to
squalamine for the whole duration of the experiment.
Thrashing assays.At different ages, animals were placed in a drop of
M9 buffer and allowed to recover for 30 s (to avoid observing
behavior associated with stress) after which the number of body
bends was counted for either 30 s or 1 min. For blinded motility
assays, adult animals were randomly picked from the treated and
untreated populations and measured for motility without knowledge
of the squalamine concentration. Thirty animals were counted in
each experiment unless stated otherwise. Experiments were carried
out in triplicate and the data from one representative experiment are
shown in Fig. S4. Statistical analysis was performed using Graphpad
Prism software (GraphPad Software) (37).
Automated motility assay. All C. elegans populations were cultured
at 20 °C and developmentally synchronized from a 4-h egg lay. At
64–72 h post-egg lay (time 0) individuals were transferred to
FUDR plates or into multiwells and body movements were
assessed over the times indicated. For experiments carried out
on agar plates, at different ages, the animals were washed off the
plates with M9 buffer and spread over an OP50 unseeded 6-cm
plate, after which their movements were recorded at 30 fps, using
a novel microscopic setup for 30 s or 1 min. For screenings in
multiwells, worms were mixed on a bench-top plate shaker at
700 rpm for 7 min to evenly distribute sedimented OP50 and
induce full worm motility. Immediately after shaking, worms
were staged on the platform for imaging. File collection was
initiated 60 s after shaking. Up to 200 animals were counted in
each experiment unless stated otherwise. One experiment that is
representative of the three measured is shown in Fig. 5. Movies
were analyzed using a custom-made tracking code.
Paralysis assays. Paralysis assays were performed by transferring L4
larvae synchronized animals to NGM plates and they were grown
at 15 °C until the first day of adulthood (2 d after L4) to avoid
developmental defects of the vulva. The L4 larvae or the young
adult animals were transferred to squalamine plates containing
FUDR and the temperature was raised to 20 °C. Each individual
experiment was initiated with 100 L4 or young adult animals per
strain. The animals were tested for paralysis by tapping their
noses and tails, prodding with a platinum wire as described
previously (53) every day for 14 consecutive days. Worms that
moved their noses but failed to move their bodies were scored as
paralyzed. Data from one representative of three experiments
are shown in Fig. S5. Analysis was performed using Graphpad
Prism software (GraphPad Software) (37).
Quantification of inclusions. To monitor the number of inclusions in
each worm, individual animals were mounted on 2% agarose
pads, containing 40 mM NaN3 as an anesthetic, on glass mi-
croscope slides for imaging. For quantification of the number of
inclusions in α-synuclein:YFP animals, only the frontal region of
the worms was considered (25). The number of inclusions in
each animal was quantified using a Leica MZ16 FA fluorescence
dissection stereomicroscope (Leica Microsystems) at a nominal
magnification of 20× or 40×, and images were acquired using an
Evolve512 Delta EMCCD camera, with high quantum efficiency
(Photometrics). Measurements on inclusions were performed
using ImageJ software (54) (National Institutes of Health). At
least 50 animals were examined per condition, unless stated
otherwise. All experiments were carried out in triplicate and the
data from one representative experiment are shown in Figs. 4
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and 5. Student’s t test was used to calculate P values, and all tests
were two-tailed unpaired unless otherwise stated.
Western blot analysis. For comparison of α-synuclein levels, ca.
3,000 adults were collected in S-basal (52) in triplicate and then
frozen in liquid N2. Samples were then extracted in Urea/SDS
buffer (8 M urea, 2% SDS, 50 mM Tris, 1× proteinase inhibitors)
(Roche Holding) and disrupted via sonication. Samples at the
appropriate concentration were added to NuPAGE LDS Sample
Buffer (1×) and NuPAGE Sample Reducing Agent (1×) (Life
Technologies) and heated at 70 °C for 10 min. The material was
resolved via NuPAGE Novex 4–12% Bis-Tris Protein Gels (Life
Technologies) and then transferred to nitrocellulose membranes,
using an iBlot Dry Blotting System (Life Technologies), and
blocked overnight at 4 °C in 5% BSA. Membranes were then
probed at room temperature with SYN-1 anti–α-synuclein anti-
body, clone 42 (BD Biosciences) 1:500. Anti–α-tubulin, clone
B-5-1-2 (Sigma-Aldrich) 1:10,000, was used to standardize total
protein loading. An Alexa 488-conjugated secondary antibody,
A11029 (Life Technologies), was used for detection.
SI Text
AutomatedMotility Assay.We built a simple, robust, compact, cost-
effective and high-throughput setup to track C. elegans during
swimming and crawling. An LED backlight illuminator with long
life span and flicker-free and shadow-free illumination was used
to illuminate worms moving in M9 buffer on a thin agar plate or
in multiwells. The swimming worms were visualized by using a
high-performance imaging lens and a machine vision camera.
The movies of the swimming worms were taken at a high number
of fps for 30 s or 1 min. Different fields of view were obtained
simply by changing the distance between the sample and the lens,
for a fixed focal length of the lens and camera sensor size. Using
this setup we were able to image successfully at the same time up
to 200 swimming animals over the whole surface of a 6-cm agar
plate or inside multiwells.
To analyze the worm movement from the movies, the first step
was to detect and subtract the background. If all worms are alive,
this procedure can be carried out by temporally averaging the
movies. If some of the worms are dead, however, this method will
skew the final statistics because the dead worms will be taken as
part of the background and thus not be included in the signal. This
is particularly important for high-throughput testing of drugs,
because certain drugs might influence the life-to-death ratio and
paralysis rate. Thus, the background must be estimated without
using temporal information. In our method we begin by defining a
Gaussian adaptive threshold of the image in such a way that all
worms are identified. Such a threshold that ensures detection of
all worms will also incorrectly elaborate some of the background
signal as worms and so is not a completely reliable detection
mechanism in itself. All pixels marked as worms are then
recalculated by interpolating from pixels not marked as worms.
This procedure avoids removing the dead worms as part of the
background. The method requires the movie to be quite regular,
however, and hence other items, such as the edge of a Petri dish,
must first be masked by other methods. After background sub-
traction a second (nonadaptive) thresholding procedure is per-
formed. Morphological operations are next used to remove
speckles (morphological opening) and to close holes that can
appear in the worms after the thresholding (morphological
closing). We label all separated regions of the thresholded image
and remove all regions that have an area too small or big to be a
single worm. The remaining labeled regions are identified as
individual worms. The positions of said regions are then stored for
each frame. Subsequently these regions are linked across the
frames by standard tracking algorithms, even taking into account
a worm disappearing or overlapping in a few frames. The ec-
centricity, a measure of the ratio of the minor and major ellipse
axes, of each tracked worm can then be used to estimate the worm
bending as a function of time.
Detection of the Interaction of Squalamine with Monomeric α-Synuclein
at High Concentrations in the Absence of Lipids. The changes in the
NMR spectrum indicate that the α-synuclein–squalamine in-
teraction is in the fast exchange regime, as the residues of
α-synuclein that are affected by the binding progressively shift
their resonance positions as the concentration of squalamine is
increased; as a consequence of the broadening a loss of in-
tensity is also observed (Fig. S1). An indication that the in-
teraction involves an aggregated state of squalamine comes
from the observation that at a high squalamine concentration
some of the C-terminal residues of α-synuclein (e.g., Y136)
experience a large degree of line broadening despite showing
only modest changes in chemical shifts. Resonance broadening
is likely to result from two factors: a chemical exchange con-
tribution, caused by perturbations in chemical shifts, and an
increase in the dipolar contribution to the transverse relaxation
rate, R2, caused by the increased size of the complex. Con-
sidering that the chemical shift change for Y136 is small, the R2
contribution must dominate, suggesting that the complex is
significantly larger in size than the monomer. This finding is
consistent with the involvement of multimeric squalamine in
the interaction, analogous to the interaction between α-synu-
clein and micellar Congo Red (CR) (55).
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Fig. S1. Squalamine interacts directly with α-synuclein at high concentrations. (A) Ratios of α-synuclein HSQC peak heights in the presence of different
concentrations of squalamine compared with free α-synuclein. The sample contained 80 μM α-synuclein, and three concentrations of squalamine were tested:
60 μM (blue circles), 160 μM (violet squares), and 240 μM (red triangles). The buffer conditions were 20 mM imidazole (pH 6), 100 mM NaCl. (B) Changes in
chemical shifts measured at a frequency of 600 MHz 1H resulting from squalamine addition compared with free α-synuclein. δCS was defined as
δCS =
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
δCS +

δH
2
2r
, where δN and δH are the changes in resonance frequency (in hertz units) for
15N and 1H, respectively. The sample contained 80 μM α-synuclein,
and three concentrations of squalamine were tested: 80 μM (blue circles), 160 μM (violet squares), and 240 μM (red triangles). (C) Ratios of α-synuclein HSQC
peak heights are shown for three samples at different concentrations with a fixed squalamine:α-synuclein ratio: 80 μM α-synuclein and 240 μM squalamine
(yellow circles), 53 μM α-synuclein and 160 μM squalamine (dark blue squares), and 35 μM α-synuclein and 107 μM squalamine (green triangles).
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Fig. S2. Effect of squalamine on the size and the thermotropic properties of DMPS vesicles. (A) Change in the diameter of DMPS vesicles (100 μM) with
increasing concentrations of squalamine measured by dynamic light scattering. (B) Differential scanning calorimetry trace of 500 μM DMPS in the absence and
presence of 50 μM squalamine.
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Fig. S3. Squalamine binding to Aβ and α-synuclein fibrils. (A) Total ion current (TIC) of 10 μM squalamine (Top), TIC corresponding to the supernatant fraction
after incubation with Aβ (Middle), and α-synuclein fibrils (Bottom), respectively. Experiments were carried out in triplicate and one representative experiment is
shown. (B) TIC averaged over three independent experiments. (C) Peak area averaged over three independent experiments. α-Synuclein and Aβ fibrils were
obtained as previously described (10, 13) and incubated overnight with 10 μM squalamine.
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Fig. S4. Squalamine recovers the severe muscle paralysis associated with overexpression of α-synuclein in PD worms (25). For experiments carried out in solid
media, the protective effect is maximal at day 4 for 50 μM squalamine. Red bars, PD; blue bars, treated PD; gray bars, controls. The plots show one repre-
sentative of three experiments. Error bars represent the SEM.
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Fig. S5. Exposure to squalamine has less relevant effects on an Aβ worm model. Squalamine administration at a concentration of 1–10 μM had no significant
protective effect (e.g., no decrease in the time of the onset of the paralysis) for an Aβ worm model CL2006 (40). The plots show one representative of three
experiments.
Movie S1. The mobility of untreated control worms at day 4 of adulthood.
Movie S1
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Movie S2. The mobility of control worms treated with 50 μM squalamine at day 4 of adulthood. Squalamine does not notably affect the motility of control
worms.
Movie S2
Movie S3. The mobility of untreated PD worms at day 4 of adulthood. It is clear the motility dysfunction is induced by α-synuclein overexpression.
Movie S3
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Movie S4. The mobility of treated PD worms at day 4 of adulthood. Squalamine greatly rescues the motility dysfunction induced by α-synuclein over-
expression.
Movie S4
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